IL299756A - Isoquinoline compounds and their use in the treatment of AHR imbalance - Google Patents

Isoquinoline compounds and their use in the treatment of AHR imbalance

Info

Publication number
IL299756A
IL299756A IL299756A IL29975623A IL299756A IL 299756 A IL299756 A IL 299756A IL 299756 A IL299756 A IL 299756A IL 29975623 A IL29975623 A IL 29975623A IL 299756 A IL299756 A IL 299756A
Authority
IL
Israel
Prior art keywords
optionally substituted
alkyl
compound
group
solvate
Prior art date
Application number
IL299756A
Other languages
English (en)
Hebrew (he)
Original Assignee
Dermavant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermavant Sciences GmbH filed Critical Dermavant Sciences GmbH
Publication of IL299756A publication Critical patent/IL299756A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
IL299756A 2020-07-16 2021-05-27 Isoquinoline compounds and their use in the treatment of AHR imbalance IL299756A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063052574P 2020-07-16 2020-07-16
US202063052561P 2020-07-16 2020-07-16
PCT/US2021/034599 WO2022015423A1 (en) 2020-07-16 2021-05-27 ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE

Publications (1)

Publication Number Publication Date
IL299756A true IL299756A (en) 2023-03-01

Family

ID=79293345

Family Applications (1)

Application Number Title Priority Date Filing Date
IL299756A IL299756A (en) 2020-07-16 2021-05-27 Isoquinoline compounds and their use in the treatment of AHR imbalance

Country Status (10)

Country Link
US (5) US11267788B2 (enExample)
EP (2) EP4786453A2 (enExample)
JP (1) JP7867482B2 (enExample)
KR (1) KR20230041021A (enExample)
CN (1) CN116157387B (enExample)
AU (1) AU2021308209A1 (enExample)
CA (1) CA3185793A1 (enExample)
IL (1) IL299756A (enExample)
MX (1) MX2023000263A (enExample)
WO (1) WO2022015423A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11267788B2 (en) 2020-07-16 2022-03-08 Dermavant Sciences GmbH Isoquinoline compounds and their use in treating AhR imbalance
WO2024020170A1 (en) * 2022-07-21 2024-01-25 Allianthera (Suzhou) Biopharmaceutical Co., Ltd. Aryl hydrocarbon receptor agonist prodrugs and methods of use thereof
US20260069585A1 (en) * 2022-08-30 2026-03-12 Dermavant Sciences GmbH ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES
WO2024152993A1 (zh) * 2023-01-17 2024-07-25 上海泽德曼医药科技有限公司 稠环类化合物、其制备方法及其在医药上的应用
CN117447402A (zh) * 2023-10-18 2024-01-26 德明药泰生物技术(深圳)有限公司 芳香烃受体调节剂类化合物及其制备方法和应用
CN117229208B (zh) * 2023-11-13 2024-02-23 上海泽德曼医药科技有限公司 稠环类化合物、其制备方法及其在医药上的应用
WO2026083733A1 (ja) * 2024-10-18 2026-04-23 株式会社ヤクルト本社 試験方法、ゲル状組成物、及び試験装置
WO2026096218A1 (en) * 2024-10-18 2026-05-07 Dermavant Sciences GmbH Pharmaceutical compositions for respiratory administration and methods of treating inflammatory diseases of the lungs
WO2026085237A1 (en) * 2024-10-18 2026-04-23 Dermavant Sciences GmbH Process for preparing 2-isopropyl-5-(isoquinolin-3-yl)benzene-1,3-diol

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06504791A (ja) 1991-04-10 1994-06-02 オクタマー,インコーポレイティド レトロウィルス複製の阻害のための方法
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
WO1999018077A1 (en) * 1997-10-02 1999-04-15 Eisai Co., Ltd. Fused pyridine derivatives
DE60233414D1 (de) 2001-07-09 2009-10-01 Combinatorx Inc Kombinationen für die behandlung entzündlicher erkrankungen
CN1596240A (zh) 2001-12-19 2005-03-16 阿特罗吉尼克斯公司 查耳酮衍生物及其治疗疾病的用途
WO2003053359A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
EP1704856A4 (en) 2003-12-26 2009-08-19 Kyowa Hakko Kirin Co Ltd PROTEIN INHIBITOR OF THE HSP90 FAMILY
WO2006058201A2 (en) 2004-11-23 2006-06-01 Reddy Us Therapeutics, Inc. Heterocyclic and bicyclic compounds, compositions and methods
GB0704718D0 (en) 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
EP2014651A1 (en) 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
JP5439127B2 (ja) 2009-11-13 2014-03-12 株式会社さいわいメディカル 乾癬又はアトピー性皮膚炎治療剤
US8933096B2 (en) 2010-06-09 2015-01-13 Rugers, The State University of New Jersey Antimicrobial agents
GB201216017D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
KR20150118106A (ko) 2012-12-20 2015-10-21 알데이라 테라퓨틱스, 아이엔씨. 페리-카르비놀
GB201304041D0 (en) 2013-03-06 2013-04-17 Water Jel Europ Llp Treatment and prophylaxis of radiation dermatitis
JP6899323B2 (ja) 2014-10-14 2021-07-07 ラ ホーヤ インスティテュート オブ アレルギー アンド イミュノロジー 低分子量タンパク質チロシンホスファターゼの阻害剤、及びその使用
JP7138654B2 (ja) 2017-03-29 2022-09-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 金属錯体
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
CN111699192B (zh) 2018-02-13 2024-03-08 Udc爱尔兰有限公司 金属络合物
TWI828664B (zh) 2018-03-19 2024-01-11 愛爾蘭商Udc愛爾蘭責任有限公司 金屬錯合物
US11267788B2 (en) 2020-07-16 2022-03-08 Dermavant Sciences GmbH Isoquinoline compounds and their use in treating AhR imbalance
WO2023020512A1 (zh) * 2021-08-16 2023-02-23 成都奥睿药业有限公司 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途
CN116947799B (zh) * 2023-03-08 2024-05-03 上海泽德曼医药科技有限公司 酚类化合物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
WO2022015423A1 (en) 2022-01-20
US20230124135A1 (en) 2023-04-20
US11267788B2 (en) 2022-03-08
JP7867482B2 (ja) 2026-05-29
EP4185566A4 (en) 2024-12-04
EP4185566A1 (en) 2023-05-31
US20240208910A1 (en) 2024-06-27
EP4786453A2 (en) 2026-08-05
US20250282730A1 (en) 2025-09-11
US20220153703A1 (en) 2022-05-19
AU2021308209A8 (en) 2023-04-13
US11827605B2 (en) 2023-11-28
US12252471B2 (en) 2025-03-18
US20220017468A1 (en) 2022-01-20
CN116157387A (zh) 2023-05-23
US11548853B2 (en) 2023-01-10
EP4185566B1 (en) 2026-06-24
CN116157387B (zh) 2026-06-09
CA3185793A1 (en) 2022-01-20
MX2023000263A (es) 2023-03-29
JP2023533855A (ja) 2023-08-04
AU2021308209A1 (en) 2023-02-09
KR20230041021A (ko) 2023-03-23

Similar Documents

Publication Publication Date Title
US12252471B2 (en) Isoquinoline compounds and their use in treating AhR imbalance
US11535606B2 (en) Substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof
WO2021238827A1 (zh) Egfr抑制剂、其制备方法及用途
EP2125803B1 (fr) Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations
CN102408429A (zh) 抑制醛甾酮合酶和芳香酶的稠合咪唑并衍生物
WO2017129116A1 (zh) 吡咯嘧啶五元氮杂环衍生物及其应用
US20240216361A1 (en) Ror-gamma modulators
JP2022529311A (ja) Tyk2偽キナーゼリガンド
NO325401B1 (no) Laktamforbindelser, anvendelse av slike samt farmasoytisk preparat inneholdende nevnte laktamforbindelser
CN103533938A (zh) 用于在盘状狼疮中使用的2,4取代的嘧啶二胺
US20160102058A1 (en) Fluoro-perhexiline compounds and their therapeutic use
EP4183785A1 (en) Novel n-heterocyclic bet bromodomain inhibitor, and preparation method therefor and medical use thereof
WO2024088282A1 (zh) 一种哒嗪酰胺类化合物、其药物组合物及其作为tyk2抑制剂的用途
US20260069585A1 (en) ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES
CN117999072A (zh) β肾上腺素能激动剂和其使用方法
HK40080028B (en) Tyk2 pseudokinase ligands
GB2560769A (en) Compounds and compositions for use in treating psoriasis
HK40087840A (en) Novel n-heterocyclic bet bromodomain inhibitor, and preparation method therefor and medical use thereof
HK40066192A (zh) Tyk2假激酶配体
JPH08268949A (ja) ジフェニルメチレン誘導体
HK40066192B (en) Tyk2 pseudokinase ligands